Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yung Ly | - |
dc.contributor.author | Joung, Boyoung | - |
dc.contributor.author | On, Young Keun | - |
dc.contributor.author | Shim, Chi Young | - |
dc.contributor.author | Lee, Moon Hyoung | - |
dc.contributor.author | Kim, Young-Hoon | - |
dc.contributor.author | Pak, Hui-Nam | - |
dc.date.accessioned | 2021-09-06T10:44:09Z | - |
dc.date.available | 2021-09-06T10:44:09Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2012-01-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106223 | - |
dc.description.abstract | Purpose: Atrial fibrillation (AF) is one of the major risk factors for ischemic stroke, and 90% of thromboembolisms in these patients arise from the left atrial appendage (LAA). Recently, it has been documented that an LAA occlusion device (OD) is not inferior to warfarin therapy, and that it reduces mortality and risk of stroke in patients with AF. Materials and Methods: We implanted LAA-ODs in 5 Korean patients (all male, 59.8 +/- 7.3 years old) with long-standing persistent AF or permanent AF via a percutaneous trans-septal approach. Results: I) The major reasons for LAA-OD implantation were high risk of recurrent stroke (80%), labile international neutralizing ratio with hemorrhage (60%), and 3/5 (60%) patients had a past history of failed carchoversion for rhythm control. 2) The mean LA size was 51.3 +/- 5.0 mm and LAA size was 25.1 x30.1 mm. We implanted the LAA-OD (28.8 +/- 3.4 mm device) successfully in all 5 patients with no complications. 3) After eight weeks of anticoagulation, all patients switched from warfarin to anti-platelet agent after confirmation of successful LAA occlusion by transesophageal echocardiography. Conclusion: We report on our early experience with LAA-OD deployment in patients with 1) persistent or permanent AF who cannot tolerate anticoagulation despite significant risk of ischemic stroke, or 2) recurrent stroke in patients who are unable to maintain sinus rhythm. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | YONSEI UNIV COLLEGE MEDICINE | - |
dc.subject | SPONTANEOUS ECHO CONTRAST | - |
dc.subject | STROKE PREVENTION | - |
dc.subject | RHYTHM MANAGEMENT | - |
dc.subject | NODE DYSFUNCTION | - |
dc.subject | WARFARIN THERAPY | - |
dc.subject | RISK-FACTORS | - |
dc.subject | ANTICOAGULATION | - |
dc.subject | TRIAL | - |
dc.subject | ASPIRIN | - |
dc.subject | EVENTS | - |
dc.title | Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young-Hoon | - |
dc.identifier.doi | 10.3349/ymj.2012.53.1.83 | - |
dc.identifier.scopusid | 2-s2.0-84455194799 | - |
dc.identifier.wosid | 000298715600009 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.53, no.1, pp.83 - 90 | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.citation.title | YONSEI MEDICAL JOURNAL | - |
dc.citation.volume | 53 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 83 | - |
dc.citation.endPage | 90 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001612998 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | SPONTANEOUS ECHO CONTRAST | - |
dc.subject.keywordPlus | STROKE PREVENTION | - |
dc.subject.keywordPlus | RHYTHM MANAGEMENT | - |
dc.subject.keywordPlus | NODE DYSFUNCTION | - |
dc.subject.keywordPlus | WARFARIN THERAPY | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | ANTICOAGULATION | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | left atrial appendage | - |
dc.subject.keywordAuthor | occlusion device | - |
dc.subject.keywordAuthor | thromboembolism | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.